Table 1 Demographic Data of Participants Completing Cognitive Testing Before and After Intravenous Chemotherapy (n = 142)
Factor | Number | Percentage |
|---|---|---|
Age, years | ||
 Average | 54.7 | |
 Median | 55.5 | |
 Range | 30–80 | |
Gender | ||
 Male | 42 | 29.6 |
 Female | 100 | 70.4 |
Cancer Type | ||
 Breast Cancer | 73 | 51.4 |
 Colorectal Cancer | 69 | 48.6 |
Treatment Setting | ||
 Neoadjuvant | 19 | 13.4 |
 Adjuvant | 80 | 56.3 |
 Metastatic/Palliative | 43 | 30.3 |
Prior Chemotherapy Exposure | ||
 Chemotherapy Naïve | 17 | 12.0 |
 Prior Chemotherapy Exposure | 125 | 88.0 |
Pre-Chemotherapy Testing Timing | ||
 Same day as chemotherapy | 106 | 74.6 |
 Day prior to chemotherapy | 36 | 25.4 |
Antineoplastic Regimen Used | ||
Breast Cancer Regimens | ||
 5-Fluorouracil/Epirubicin/Cyclophosphamide (FEC) | 21 | 14.8 |
 Docetaxel (D) | 21 | 14.8 |
 Docetaxel/Cyclophosphamide (DC) | 14 | 9.9 |
 Paclitaxel (P) | 11 | 7.7 |
 Docetaxel/Carboplatin (DCARB) | 4 | 2.8 |
 Doxorubicin/Cyclophosphamide (AC) | 2 | 1.4 |
Colorectal Cancer Regimens | ||
 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFOX) | 45 | 31.7 |
 5-Fluorouracil/Leucovorin/Irinotecan (FOLFIRI) | 11 | 7.7 |
 Capecitabine/Oxaliplatin (CAPOX) | 9 | 6.3 |
 5-Fluorouracil/Leucovorin (FUFA) | 2 | 1.4 |
 Irinotecan | 2 | 1.4 |
Additional Antineoplastic Medications Used | ||
 Trastuzumab | 16 | 11.3 |
 Bevacizumab | 12 | 8.5 |
 Pertuzumab | 2 | 1.4 |
 Panitumumab | 2 | 1.4 |
Supportive Medications Used | ||
 Steroids | 142 | 100.0 |
 Benzodiazepinesa | 0 | 0.0 |
 Diphenhydramine | 54 | 38.0 |